RhumbLine Advisers
TYRA icon

RhumbLine Advisers’s Tyra Biosciences TYRA Stock Holding History

RhumbLine Advisers’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Buy
39,660
+870
+2% +$28.2K ﹤0.01% 2004
2025
Q4 		$1.02M Sell
38,790
-1,846
-5% -$33.9K ﹤0.01% 2214
2025
Q3 		$568K Sell
40,636
-49
-0.1% -$559 ﹤0.01% 2609
2025
Q2 		$389K Buy
40,685
+12,604
+45% +$120K ﹤0.01% 2838
2025
Q1 		$261K Buy
28,081
+1,879
+7% +$24.3K ﹤0.01% 2969
2024
Q4 		$364K Buy
26,202
+1,027
+4% +$18.6K ﹤0.01% 2872
2024
Q3 		$592K Buy
25,175
+1,603
+7% +$33.7K ﹤0.01% 2590
2024
Q2 		$377K Buy
23,572
+2,574
+12% +$44.3K ﹤0.01% 2854
2024
Q1 		$344K Sell
20,998
-334
-2% -$5.48K ﹤0.01% 2900
2023
Q4 		$295K Sell
21,332
-129
-0.6% -$1.67K ﹤0.01% 2983
2023
Q3 		$296K Buy
21,461
+176
+0.8% +$2.61K ﹤0.01% 2943
2023
Q2 		$362K Sell
21,285
-641
-3% -$9.3K ﹤0.01% 2889
2023
Q1 		$352K Buy
21,926
+1,178
+6% +$14K ﹤0.01% 2564
2022
Q4 		$158K Buy
20,748
+115
+0.6% +$813 ﹤0.01% 2841
2022
Q3 		$181K Buy
20,633
+3,348
+19% +$30.6K ﹤0.01% 2918
2022
Q2 		$124K Buy
17,285
+5,559
+47% +$44.3K ﹤0.01% 3014
2022
Q1 		$125K Buy
+11,726
New +$139K ﹤0.01% 2848

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RhumbLine Advisers's TYRA Position: Q1 2026 in Review

RhumbLine Advisers increased its Tyra Biosciences (TYRA) stake by 2.2% in Q1 2026, buying an estimated $28.2K and bringing the position to 39,660 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

RhumbLine Advisers first reported a position in TYRA in Q1 2022 and has held it in 17 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • RhumbLine Advisers held 39,660 shares of Tyra Biosciences worth $1.52M as of Q1 2026.
  • RhumbLine Advisers bought 870 Tyra Biosciences shares in Q1 2026, an estimated $28.2K.
  • Tyra Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2004 holding.
  • RhumbLine Advisers first reported a position in Tyra Biosciences in Q1 2022 and has held it in 17 quarters since.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.